Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology (Internal Medicine) Physician in Columbus, OH
NPI: 1114288859Primary Practice Location
OHIO STATE UNIVERSITY STATE HEALTH SYSTEM
1670 Upham Dr, Columbus, OH
Primary Employer
OSU Internal Medicine
wexnermedical.osu.edu
HQ Phone
Get M.D. David's Phone Numberphone_androidMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
OH State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 50 | 67 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 45 | 100 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 41 | 157 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 21 | 21 |
| 5 | 99239Hospital discharge day management, more than 30 minutes | 17 | 17 |
Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy.
Authors: Beth Christian, Yazeed Sawalha, John Reneau, Lapo Alinari, Kaitlin Annunzio, Timothy Voorhees, Narendranath Epperla, Kami Maddocks, Michael Cackovic, Robert Baiocchi
Journal: Blood Adv
Targeting BTK in CLL: Beyond Ibrutinib.
Authors: Jennifer Woyach
Journal: Curr Hematol Malig Rep
Authors: Beth Christian, Yazeed Sawalha, Audrey Sigmund, Lapo Alinari, Kaitlin Annunzio, Timothy Voorhees, Narendranath Epperla, Kami Maddocks, Havi Rosen, Robert Baiocchi
Journal: Hematol Oncol
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: lenalidomide, DRUG: VAY736
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT), DRUG: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Lead Sponsor: David Bond, MD
Collaborators: Bristol-Myers Squibb
Intervention / Treatment: BIOLOGICAL: Nivolumab, DRUG: Cyclophosphamide, DRUG: Prednisone, DRUG: Etoposide, DRUG: Vincristine Sulfate, BIOLOGICAL: Rituximab, DRUG: Doxorubicin Hydrochloride
